Hoffmann-La Roche: Carcinoma, Basal Cell trials

The registry lists 13 Carcinoma, Basal Cell studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 6No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell CarcinomaTerminatedNCT01898598Phase 2Results posted
• A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell CarcinomasCompletedNCT01815840Phase 2Results posted
• STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaCompletedNCT01367665Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell CarcinomaCompletedNCT01201915Phase 2Results posted
• A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy ExistsCompletedNCT00968981Phase 1Results posted
• A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyCompletedNCT00959647Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell CarcinomaCompletedNCT00833417Phase 2Results posted
• Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)CompletedNCT02674009
• Observational Study of Vismodegib (Erivedge) in Patients Treated in ArgentinaCompletedNCT02438644
• A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)CompletedNCT02371967
• An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer ParticipantsCompletedNCT02100111
• An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)TerminatedNCT01604252
• A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaApproved for marketingNCT01160250